MA54379A - Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant - Google Patents
Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenantInfo
- Publication number
- MA54379A MA54379A MA054379A MA54379A MA54379A MA 54379 A MA54379 A MA 54379A MA 054379 A MA054379 A MA 054379A MA 54379 A MA54379 A MA 54379A MA 54379 A MA54379 A MA 54379A
- Authority
- MA
- Morocco
- Prior art keywords
- mcl
- inhibitor
- preparation
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634 | 2018-12-06 | ||
| PCT/EP2019/083773 WO2020115183A1 (fr) | 2018-12-06 | 2019-12-05 | Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54379A true MA54379A (fr) | 2021-10-13 |
| MA54379B1 MA54379B1 (fr) | 2023-12-29 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54379A MA54379B1 (fr) | 2018-12-06 | 2019-12-05 | Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220017533A1 (fr) |
| EP (1) | EP3891156B1 (fr) |
| JP (1) | JP2022511495A (fr) |
| KR (1) | KR20210100148A (fr) |
| CN (1) | CN113166169A (fr) |
| AR (1) | AR117255A1 (fr) |
| BR (1) | BR112021010072A2 (fr) |
| CA (1) | CA3121363A1 (fr) |
| DK (1) | DK3891156T3 (fr) |
| EA (1) | EA202191534A1 (fr) |
| ES (1) | ES2971258T3 (fr) |
| FI (1) | FI3891156T3 (fr) |
| HR (1) | HRP20240211T1 (fr) |
| HU (1) | HUE065266T2 (fr) |
| IL (1) | IL283656A (fr) |
| LT (1) | LT3891156T (fr) |
| MA (1) | MA54379B1 (fr) |
| MD (1) | MD3891156T2 (fr) |
| MX (1) | MX2021006702A (fr) |
| PL (1) | PL3891156T3 (fr) |
| PT (1) | PT3891156T (fr) |
| RS (1) | RS65047B1 (fr) |
| SI (1) | SI3891156T1 (fr) |
| TW (1) | TW202039511A (fr) |
| WO (1) | WO2020115183A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3222269A1 (fr) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des agents anticancereux |
| EP4351657A1 (fr) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
- 2019-12-05 TW TW108144437A patent/TW202039511A/zh unknown
- 2019-12-05 CA CA3121363A patent/CA3121363A1/fr active Pending
- 2019-12-05 US US17/295,521 patent/US20220017533A1/en active Pending
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 JP JP2021531796A patent/JP2022511495A/ja active Pending
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/fr active Active
- 2019-12-05 KR KR1020217020808A patent/KR20210100148A/ko unknown
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 MD MDE20210991T patent/MD3891156T2/ro unknown
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/fr active Application Filing
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
-
2021
- 2021-06-02 IL IL283656A patent/IL283656A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3891156T3 (fi) | 2024-02-07 |
| EP3891156A1 (fr) | 2021-10-13 |
| SI3891156T1 (sl) | 2024-03-29 |
| LT3891156T (lt) | 2023-12-27 |
| IL283656A (en) | 2021-07-29 |
| US20220017533A1 (en) | 2022-01-20 |
| CN113166169A (zh) | 2021-07-23 |
| AU2019391329A1 (en) | 2021-07-01 |
| WO2020115183A1 (fr) | 2020-06-11 |
| PL3891156T3 (pl) | 2024-05-13 |
| BR112021010072A2 (pt) | 2021-08-24 |
| AR117255A1 (es) | 2021-07-21 |
| PT3891156T (pt) | 2024-01-16 |
| KR20210100148A (ko) | 2021-08-13 |
| MD3891156T2 (ro) | 2024-06-30 |
| EA202191534A1 (ru) | 2021-10-27 |
| ES2971258T3 (es) | 2024-06-04 |
| HUE065266T2 (hu) | 2024-05-28 |
| TW202039511A (zh) | 2020-11-01 |
| JP2022511495A (ja) | 2022-01-31 |
| HRP20240211T1 (hr) | 2024-04-26 |
| DK3891156T3 (da) | 2024-02-19 |
| MA54379B1 (fr) | 2023-12-29 |
| RS65047B1 (sr) | 2024-02-29 |
| EP3891156B1 (fr) | 2023-11-15 |
| MX2021006702A (es) | 2021-07-07 |
| CA3121363A1 (fr) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000751A1 (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419) | |
| CY1124257T1 (el) | N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA | |
| CY1123260T1 (el) | Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου | |
| MD3601283T2 (ro) | Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
| MA42946B1 (fr) | Sels et formes solides d'un antibiotique de type monobactame | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| EA202190356A1 (ru) | Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов | |
| MA54379A (fr) | Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant | |
| AR072611A1 (es) | Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne. | |
| BRPI0416287A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| WO2018183631A8 (fr) | Nouvelles formulations pharmaceutiques contenant de l'indirubine et des dérivés de celui-ci et procédés de fabrication et d'utilisation de celles-ci | |
| BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
| MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
| MA54063A (fr) | Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenant | |
| MA53900A (fr) | Nouveaux dérivés d'amino-pyrimidonyl-pipéridinyl, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок | |
| MA54541A (fr) | Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées | |
| MA53099A (fr) | Formes d'ivosidénib et compositions pharmaceutiques | |
| EA202190452A1 (ru) | Ингибиторы cdk8/19 |